Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: Implementations include a computer-implemented method for reducing cyber-security risk, comprising: accessing a knowledge mesh including a plurality of modules, wherein each module is associated with a respective aspect and maintains a knowledge graph specific to the respective aspect, wherein each knowledge graph is generated using data from one or more cyber-security repositories and includes nodes and connections between the nodes; performing an information completion process to generate connections between nodes of knowledge graphs maintained by different modules of the knowledge mesh, including performing at least one of: inheritance-based inference; natural language processing classifier-based inference; or natural language processing-based object matching inference; and identifying, using the generated connections between the nodes of the knowledge graphs, one or more actions to reduce cyber-security risk.

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).

Abstract: In some embodiments, systems and methods described herein are directed to using smart meters to determine an operational status of an asset. In some embodiments, the asset is a transformer. In some embodiments, the system receives data from the smart meters such as voltage and associates the data with an asset feeding electricity to the smart meter. In some embodiments, the system includes a data analytics platform that can generate a failure probability prediction using the smart meter data. In some embodiments, the system includes an AI model configured to receive smart meter data, execute a decision analysis, and return a designation of whether the asset is at risk of failure or has failed.

Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).

Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: A materials handling vehicle operating system is provided comprising a tag layout where a plurality of entry/exit tag sets are arranged along a travel path at different ones of the entry/exit thresholds of a restricted navigation zone. Each entry/exit tag set comprises a release tag, a restriction tag, and an indicator tag. The indicator tag is positioned between the restriction tag and the restricted navigation zone. The restriction tag is positioned between the release tag and the indicator tag. The tag reader and the reader module cooperate to compare identified tag data with stored tag data and initiate a remediation operation when an indicator tag is identified in place of a restriction tag. Tag layouts for one-way and two-way travel into and out of a restricted navigation zone are also contemplated.

Abstract: The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising: administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the individual.

Abstract: The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising: administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the individual.

Abstract: This application relates to a method of treatment with the NK-1 antagonist, tradipitant.

Abstract: A device for cold rolling a thread on a tubular support member of a rotary shouldered thread connection includes obtaining an original root depth of a thread root, cold rolling the thread until a minimum increased root depth tolerance is achieved.

Abstract: Techniques regarding manufacturing one or more digital product designs are provided. For example, one or more embodiments described herein can include a system, which can comprise a memory that can store computer executable components. The system can also comprise a processor, operably coupled to the memory, and that can execute the computer executable components stored in the memory. The computer executable components can comprise a user interface component that generates a manufacturability report regarding a product design in relation to a manufacturing process. The manufacturability report can indicate whether a product feature included in the product design is permissible based on a plurality of manufacturing considerations associated with the manufacturing process.